On November 15, East China Pharmaceutical (000963.SZ) issued an announcement saying that American partner IMMUNOGEN, Inc. announced that it was used to treat the global FIRST-in-CLASS ADC drug Elahere ? (FIRST-In-Class) ADC (FIRST-In-Class) ADC (FIRT Mirvetuximab Soravtansine-GYNX, R & D code: IMGN853, HDM2002) obtained the Accelerated approval of the US Food and Drug Administration (FDA).
Elahere ? has also become the first ADC drug approved by the FDA for platinum resistant ovarian cancer, which is used to treat folic acid receptor α (FRα) positive and previously accepted 1-3-line systemic treatment plan Adult patients with epithelial cancer, fallopian tube cancer or primary peritoneal cancer.